Glucagon is a Synthetic Peptide owned by Xeris Biopharma Holdings, and is involved in 21 clinical trials, of which 20 were completed, and 1 is planned.

Glucagon is a glucagon receptor agonist. Glucagon binds to  the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion.

Glucagon xerisol acts by agonizing glucagon receptor. It acts by binding to glucagon receptor which is a G protein-coupled receptor located in the plasma membrane. Glucagon initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme activates phosphorylase kinase which in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood.

The revenue for Glucagon is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Glucagon NPV Report.

Glucagon is currently owned by Xeris Biopharma Holdings.

Glucagon Overview

Glucagon (Gvoke, Ogluo) is an anti-hypoglycemic agent. It is formulated as single-dose pre-filled hypopen auto-injector solution for subcutaneous route of administration. Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Ogluo injection is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus and type 1 diabetes (juvenile diabetes) and type 2 diabetes, post-bariatric hypoglycemia and gastroenterology disorders.

Glucagon is under development for the prevention of exercise-induced hypoglycemia.

Glucagon is under development for the treatment of congenital hyperinsulinism (CH). 

Glucagon was under development for the treatment of neurology. 

Xeris Biopharma Holdings Overview

Xeris Biopharma Holdings (XERIS) is the specialty pharmaceutical company that develops novel technology platforms to develop and commercialize stable injectable and infusible drug formulations. The company’s XeriSol formulation technology enables the subcutaneous and intramuscular delivery of concentrated formulations of proteins, peptides, antibodies and small molecules using syringes, multi-dose pens, auto-injectors and pumps. XERIS’s products are used in therapeutic areas such as severe hypoglycemia, post-bariatric hypoglycemia, congenital hyperinsulinism, hypoglycemia-associated autonomic failure, exercise-induced hypoglycemia, acute repetitive seizures and type 1/type 2 blood sugar controls. It caters to caregivers, health practitioners and patients. XERIS is headquartered in Chicago, Illinois, the US.

The company reported revenues of (US Dollars) US$49.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$20.4 million in FY2020. The operating loss of the company was US$115.2 million in FY2021, compared to an operating loss of US$84.3 million in FY2020. The net loss of the company was US$122.7 million in FY2021, compared to a net loss of US$91.1 million in FY2020. The company reported revenues of US$29.7 million for the third quarter ended September 2022, an increase of 17.5% over the previous quarter.

Quick View – Glucagon

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Glucagon
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.